We did not find significant differences in transcript abundances when comparing RNA-sequencing derived transcriptomes for RASSF7 amplifications to other tumours; or for lesions in Hippo signalling genes (NF2, LATS1, LATS2) singly or combined; or for mesotheliomas with or without SETD mutations. The gene discussed is NF2; the disease is mesothelioma.